AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17608947 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgery (current standard treatment)
Number of subjects: 120
Study 16258576 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Parents-Strong Children programme (6-week behavioural intervention)
Number of subjects: 0
Study 16258576 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list control design)
Number of subjects: 0
Study 12435257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 4052
Study 12435257 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 4052
Study 10202575 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 bolus injection
Number of subjects: 0
Study 10202575 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory anxiety scan
Number of subjects: 0
Study 7847642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole (450 mg/m2 body surface area intravenously daily for 5 days and then weekly for 48 weeks, plus levamisole 50 mg orally three times/d for 3 days, repeated every 2 weeks for 1 year)
Number of subjects: 929
Study 7847642 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole alone (50 mg orally three times/d for 3 days, repeated every 2 weeks for 1 year)
Number of subjects: 929
Study 7847642 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 929
Study 2335063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program (learning by teaching)
Number of subjects: 8
Study 2335063 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-equivalent)
Number of subjects: 8
Study 31081404 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Number of subjects: 160
Study 31081404 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC, 50 mg)
Number of subjects: 160
Study 28904053 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg olmesartan + 12.5 mg hydrochlorothiazide (OH)
Number of subjects: 481
Study 28904053 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg telmisartan + 5 mg amlodipine (TA)
Number of subjects: 481
Study 25907406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I), 5 sessions
Number of subjects: 23
Study 25907406 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 23
Study 22618564 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release with nerve conduction studies (n = 45)
Number of subjects: 93
Study 22618564 — intervention group
Group type: COMPARATOR
Intervention: Carpal tunnel release without nerve conduction studies (n = 48)
Number of subjects: 93
Study 21311416 — intervention group
Group type: COMPARATOR
Intervention: Isoflavones 60 mg + Lactobacillus sporogenes + calcium and vitamin D3 (E)
Number of subjects: 634
Study 21311416 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnolia bark extract + Isoflavones + Lactobacillus sporogenes + calcium and vitamin D3 (ES)
Number of subjects: 634
Study 21311416 — intervention group
Group type: COMPARATOR
Intervention: Both E and ES
Number of subjects: 634
Study 21311416 — intervention group
Group type: COMPARATOR
Intervention: E
Number of subjects: 634
Study 21311416 — intervention group
Group type: EXPERIMENTAL
Intervention: ES
Number of subjects: 634
Study 19289934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trial (RCT)
Number of subjects: 0
Study 19289934 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 16954712 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 40
Study 16954712 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.25%
Number of subjects: 40
Study 15577584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1110 MBq (30 mCi) 131I dose
Number of subjects: 155
Study 15577584 — intervention group
Group type: EXPERIMENTAL
Intervention: 3700 MBq (100 mCi) 131I dose
Number of subjects: 155
Study 11912569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion, Sertraline, Venlafaxine (doses: bupropion 450 mg/day, sertraline 200 mg/day, venlafaxine 375 mg/day)
Number of subjects: 64
Study 11912569 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase (not specified which antidepressant continued)
Number of subjects: 64
Study 9396908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 69
Study 9396908 — intervention group
Group type: COMPARATOR
Intervention: No epidural anesthesia
Number of subjects: 69
Study 8164529 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 0
Study 8164529 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exertion
Number of subjects: 0
Study 8164529 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate amounts of exercise
Number of subjects: 0
Study 3073870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg/day prednisolone for 3 weeks, then 0.3 mg/kg for a fourth week + 5 MU/m2 i.m. interferon for 12 weeks (5 days daily then three times a week)
Number of subjects: 20
Study 3073870 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 5 MU/m2 i.m. interferon for 12 weeks (5 days daily then three times a week)
Number of subjects: 20
Study 30045336 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily
Number of subjects: 80
Study 30045336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 80
Study 26804973 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized differential explanations of voice-hearing
Number of subjects: 1004
Study 26804973 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported behavioral intentions
Number of subjects: 1004
Study 25697549 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Lactobacillus fermentum CECT5716 (experimental group, EG)
Number of subjects: 0
Study 25697549 — intervention group
Group type: COMPARATOR
Intervention: Control formula without Lactobacillus fermentum CECT5716 (control group, CG)
Number of subjects: 0
Study 23588255 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (Ibumetin NYCOMED GmbH Plant Oranienburg Germany (600 mg) × 3/day/1 week)
Number of subjects: 27
Study 23588255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20004356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alpha-lipoic acid (ALA), administered daily for 3 weeks
Number of subjects: 30
Study 20004356 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered daily for 3 weeks
Number of subjects: 30
Study 19057167 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16844267 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli and bifidobacteria
Number of subjects: 479
Study 16844267 — intervention group
Group type: COMPARATOR
Intervention: Vitamins plus minerals
Number of subjects: 479
Study 12509548 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dye and alcohol treatment (n = 384)
Number of subjects: 766
Study 12509548 — intervention group
Group type: COMPARATOR
Intervention: Dry care (n = 382)
Number of subjects: 766
Study 10435201 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic olanzapine (mean daily dose at endpoint = 13.6 +/- 6.9 mg/day)
Number of subjects: 0
Study 10435201 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic olanzapine
Number of subjects: 0
Study 8777099 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine 20 ml via a low thoracic extradural catheter and a diclofenac suppository (100 mg) given 30 min before incision (group 1)
Number of subjects: 40
Study 8777099 — intervention group
Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine 20 ml via a low thoracic extradural catheter and a diclofenac suppository (100 mg) given 30 min after incision (group 2)
Number of subjects: 40
Study 8777099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received a standard general anaesthetic and no opioid was used before or during operation.
Number of subjects: 40
Study 1797522 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation programme (individual and group basis with client-centred and cognitive-behavioural therapy approaches)
Number of subjects: 239
Study 1797522 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group for 3 weeks
Number of subjects: 239
Study 6822200 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the tumour with subtotal oesophagectomy without opening the thorax.
Number of subjects: 0
Study 6822200 — intervention group
Group type: COMPARATOR
Intervention: Thoraco-abdominal or transthoracic resection.
Number of subjects: 0
Study 31526122 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neighborhood socioeconomic status
Number of subjects: 0
Study 31526122 — intervention group
Group type: EXPERIMENTAL
Intervention: Women and younger stroke survivors
Number of subjects: 0
Study 29220623 — intervention group
Group type: EXPERIMENTAL
Intervention: AgeWISE program (n = 25)
Number of subjects: 49
Study 29220623 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group (n = 24)
Number of subjects: 49
Study 26915900 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Door intervention
Number of subjects: 161
Study 26915900 — intervention group
Group type: COMPARATOR
Intervention: Service Referral control
Number of subjects: 161
Study 25439419 — intervention group
Group type: EXPERIMENTAL
Intervention: IV succinylcholine 0.3 mg/kg
Number of subjects: 180
Study 25439419 — intervention group
Group type: EXPERIMENTAL
Intervention: IV succinylcholine 0.6 mg/kg
Number of subjects: 180
Study 25439419 — intervention group
Group type: EXPERIMENTAL
Intervention: IV succinylcholine 1.0 mg/kg
Number of subjects: 180
Study 23067904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol administered before primary percutaneous coronary intervention (pPCI)
Number of subjects: 220
Study 23067904 — intervention group
Group type: COMPARATOR
Intervention: Oral metoprolol initiated post-primary percutaneous coronary intervention (pPCI)
Number of subjects: 220
Study 23067904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 220
Study 20487410 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative exposure therapy (NET) for 10 sessions
Number of subjects: 16
Study 18595960 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based violence-prevention intervention
Number of subjects: 137
Study 18595960 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational handout on literacy promotion)
Number of subjects: 137
Study 16608538 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeli suit treatment (AST)
Number of subjects: 24
Study 16608538 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 24
Study 14570964 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger management
Number of subjects: 169
Study 14570964 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression management
Number of subjects: 169
Study 14570964 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 169
Study 10695095 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (354 patients; 75%) at half their current daily dose of CFC-BDP
Number of subjects: 473
Study 10695095 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP (119 patients; 25%)
Number of subjects: 473
Study 8596569 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil (intracavernosal injection)
Number of subjects: 1180
Study 8596569 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil (minimal effective dose)
Number of subjects: 1180
Study 8596569 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil (self-injection)
Number of subjects: 1180
Study 8596569 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil (side effects)
Number of subjects: 1180
Study 1849160 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A virus vaccine (10(4.1), 10(5.2), 10(6.1), 10(7.3) TCID50)
Number of subjects: 40
Study 1849160 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A virus vaccine (10(7.3) TCID50)
Number of subjects: 40
Study 1849160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6611963 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic insertion of a Foley catheter alone
Number of subjects: 6
Study 6611963 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic administration of Tylose gel
Number of subjects: 6
Study 29249435 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 60
Study 29249435 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study 29249435 — intervention group
Group type: COMPARATOR
Intervention: RIPC vs Sham
Number of subjects: 60
Study 29249435 — intervention group
Group type: COMPARATOR
Intervention: RIPC vs Sham (adjusted for age and sex)
Number of subjects: 60
Study 28697863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (1 g intra-articularly and 50 mL intra-articular saline)
Number of subjects: 150
Study 28697863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1 g IV and 50 mL intra-articular saline)
Number of subjects: 150
Study 28697863 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 g and 50 mL intra-articular saline)
Number of subjects: 150
Study 28697863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular TXA
Number of subjects: 150
Study 28697863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA
Number of subjects: 150
Study 28697863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 25158274 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic sling
Number of subjects: 404
Study 25158274 — intervention group
Group type: COMPARATOR
Intervention: Transobturator sling
Number of subjects: 404
Study 25158274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 404
Study 23806675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat It To Beat It programme (community-based education and 'below the line' social marketing)
Number of subjects: 2804
Study 23806675 — intervention group
Group type: COMPARATOR
Intervention: Control group (New England region, no intervention)
Number of subjects: 2804
Study 21146279 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended feedback group with voice prompts
Number of subjects: 312
Study 21146279 — intervention group
Group type: COMPARATOR
Intervention: Limited feedback group with metronome and visual feedback
Number of subjects: 312
Study 18279933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ADT (6 months or longer)
Number of subjects: 48
Study 18279933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ADT (less than 6 months)
Number of subjects: 48
Study 18279933 — intervention group
Group type: COMPARATOR
Intervention: No ADT (healthy controls or prostate cancer patients not on ADT)
Number of subjects: 48
Study 18279933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ADT
Number of subjects: 48
Study 18279933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ADT
Number of subjects: 48
Study 16556072 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva) combined with carboplatin and paclitaxel chemotherapy
Number of subjects: 0
Study 16556072 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Number of subjects: 0
Study 16556072 — intervention group
Group type: COMPARATOR
Intervention: Standard first-line chemotherapy
Number of subjects: 0
Study 14601273 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-through-needle combined spinal-epidural (CSE)
Number of subjects: 89
Study 14601273 — intervention group
Group type: COMPARATOR
Intervention: Single-shot spinal (SSS)
Number of subjects: 89
Study 11784964 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (1.2 g/day for 4 days after surgery)
Number of subjects: 81
Study 11784964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 11784964 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 81
Study 9426793 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled reduced smoking
Number of subjects: 48000000
Study 8314479 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b at a dose of 6 million units (MU) three times per week
Number of subjects: 87
Study 8314479 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b at a dose of 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months
Number of subjects: 87
Study 8314479 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b at a dose of 6 MU
Number of subjects: 87
Study 2874822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 10
Study 2874822 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (15 mg)
Number of subjects: 10
Study 2874822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (1 mg)
Number of subjects: 10
Study 2874822 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 10
Study 2874822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29458407 — intervention group
Group type: EXPERIMENTAL
Intervention: ICare Prevent (guided version)
Number of subjects: 252
Study 29458407 — intervention group
Group type: EXPERIMENTAL
Intervention: ICare Prevent (unguided version)
Number of subjects: 252
Study 29458407 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 252
Study 29458407 — intervention group
Group type: EXPERIMENTAL
Intervention: ICare Prevent (both versions)
Number of subjects: 252
Study 27514722 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 18
Study 25250660 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based therapy (FBT)
Number of subjects: 164
Study 25250660 — intervention group
Group type: COMPARATOR
Intervention: Systemic family therapy (SyFT)
Number of subjects: 164
Study 24064461 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 18
Study 24064461 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 21175564 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg per week)
Number of subjects: 60
Study 21175564 — intervention group
Group type: COMPARATOR
Intervention: Fumarates (30 mg, followed by 120 mg according to a standard progressive dosage regimen)
Number of subjects: 60
Study 18331943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis
Number of subjects: 30
Study 18331943 — intervention group
Group type: COMPARATOR
Intervention: Nonpumice group
Number of subjects: 30
Study 16753768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 97
Study 16753768 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 97
Study 14706912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 14706912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with estrogen and progestational agents
Number of subjects: 0
Study 14706912 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 0
Study 11024415 — intervention group
Group type: EXPERIMENTAL
Intervention: Early average intraocular pressure greater than 17.5 mm Hg
Number of subjects: 738
Study 11024415 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of visits with intraocular pressure less than 18 mm Hg
Number of subjects: 738
Study 11024415 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 50% of visits with intraocular pressure less than 18 mm Hg
Number of subjects: 738
Study 8640295 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms potassium iodide/day
Number of subjects: 108
Study 8640295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodine supplementation)
Number of subjects: 108
Study 8640295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (iodine supplementation and control)
Number of subjects: 108
Study 1478250 — intervention group
Group type: COMPARATOR
Intervention: BIM 23014 (1000, 2000, and 3000 micrograms as a 24 h s.c. infusion)
Number of subjects: 8
Study 1478250 — intervention group
Group type: COMPARATOR
Intervention: BIM 23014 (2000 micrograms daily for 7 days as a continuous s.c. infusion)
Number of subjects: 8
Study 3884807 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (Minipress)
Number of subjects: 14
Study 31422039 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received donkey milk, Badanmu, Chamagu compound containing a variety of protein nutritional preparations 20g/d.
Number of subjects: 108
Study 31422039 — intervention group
Group type: COMPARATOR
Intervention: Control group received basic treatment combined with nutrition treatment without additional protein preparations.
Number of subjects: 108
Study 29422384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine and amodiaquine plus a single dose of 0.25 mg/kg primaquine
Number of subjects: 80
Study 29422384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus 15 mg/kg per day methylene blue for 3 days
Number of subjects: 80
Study 29422384 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine and amodiaquine
Number of subjects: 80
Study 29422384 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 80
Study 26352529 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted distal gastrectomy (LADG)
Number of subjects: 1416
Study 24655212 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 50
Study 24655212 — intervention group
Group type: COMPARATOR
Intervention: Separate group treatments of the overweight/obese parent and child (PC) - PC-1
Number of subjects: 50
Study 24655212 — intervention group
Group type: COMPARATOR
Intervention: Separate group treatments of the overweight/obese parent and child (PC) - PC-2
Number of subjects: 50
Study 22496116 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (n=101)
Number of subjects: 204